Published in July 2014
Low systolic blood pressure (SBP) is associated with poor outcomes in heart failure. Moreover, it limits the use and/or dose of recommended pharmacological agents in a substantial number of chronic heart failure patients. A SHIFT analysis assessed the efficacy and safety of ivabradine depending on the baseline SBP. The population was composed of 2110 patients with SBP <115 mm Hg, 1968 with 115≤SBP<130 mm Hg, and 2427 with SBP ≥130 mm Hg before the treatment.
The conclusion was that ivabradine was associated with a similar relative risk reduction of the primary end point of cardiovascular mortality or hospitalization for worsening heart failure in the three SBP groups (SBP <115 mm Hg, hazard ratio [HR]=0.84; 115≤SBP<130 mm Hg, HR=0.86, SBP≥130 mm Hg, HR=0.77; P interaction=0.68). It confirms that the efficacy and safety of ivabradine are similar irrespective of baseline systolic blood pressure.1

1. Komajda M et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014;16(7):810-816.